This is fair assessment. I’m personally happy with my investment risk here as the newly released proteomics sheds light on a well known adjacency pathway (think phosphokinase pi3k regulation in precision oncology etc.) in relation to the growth factors and precursory peptides that ATL1102 seems to regulate. A larger cohort size with a higher dose stratum should yield some interesting results. I do agree that the most exciting take away from the P2A is the maintenance or improvement in test scores amongst the majority of subjects.
- Forums
- ASX - By Stock
- PER
- $15m cap raise Fresh Equities at 24c
$15m cap raise Fresh Equities at 24c, page-553
-
-
- There are more pages in this discussion • 303 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.5¢ |
Change
0.001(1.19%) |
Mkt cap ! $76.63M |
Open | High | Low | Value | Volume |
8.3¢ | 8.5¢ | 8.3¢ | $32.58K | 385.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3647 | 8.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.5¢ | 8842 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3647 | 0.084 |
1 | 3577 | 0.083 |
1 | 5500 | 0.082 |
2 | 66300 | 0.080 |
2 | 212658 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.085 | 8842 | 1 |
0.086 | 6500 | 1 |
0.087 | 125000 | 1 |
0.089 | 135000 | 2 |
0.090 | 286175 | 3 |
Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |